In this issue
Insight
Why sprinting to change clinical practice guidelines on blood pressure treatment is prematureSubscription
Caution is required when the media reports on high profile medical studies.
Correspondence
Review of tramadol use within NHS Scotland following reclassificationSubscription
After growing reports of misuse and harm, including increased implication in drug-related deaths, the Advisory Council on the Misuse of Drugs recommended that tramadol should be reclassified as a class C, Schedule 3 drug. This was enacted in June 2014.
Yellow card champions to help increase reporting of adverse drug reactionsSubscription
The Yellow Card Scheme is vital in helping the Medicines and Healthcare products Regulatory Agency (MHRA) monitor the safety of medicines and vaccines that are on the market. The Yellow Card Centre Wales (YCC Wales) is one of five regional adverse drug reaction (ADR) monitoring centres acting on behalf of the MHRA.
CPD article
Chronic tic disorders: diagnosis, treatment and managementSubscription
How different types of tic disorders are diagnosed and the appropriate therapeutic options for their management, with a focus on Tourette syndrome.
Review
Primary prevention of cardiovascular disease with statins: assessing the evidence base behind clinical guidanceSubscription
Statins and other cholesterol-lowering drugs are increasingly being used for primary prevention of atherosclerotic cardiovascular disease.
Considerations in selecting pharmacological treatments for attention deficit hyperactivity disorder Subscription
Attention deficit hyperactivity disorder is highly prevalent and is associated with significant impairment across the lifespan.
